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Abstract
Background: 1q21.1 Copy Number Variant (CNV) is associated with a highly variable phenotype ranging from
congenital anomalies, learning deficits/intellectual disability (ID), to a normal phenotype. Hence, the clinical
significance of this CNV can be difficult to evaluate. Here we described the consequences of the 1q21.1 CNV on
genome-wide gene expression and function of selected candidate genes within 1q21.1 using cell lines from
clinically well described subjects.
Methods and Results: Eight subjects from 3 families were included in the study: six with a 1q21.1 deletion and
two with a 1q21.1 duplication. High resolution Affymetrix 2.7M array was used to refine the 1q21.1 CNV
breakpoints and exclude the presence of secondary CNVs of pathogenic relevance. Whole genome expression
profiling, studied in lymphoblast cell lines (LBCs) from 5 subjects, showed enrichment of genes from 1q21.1 in the
top 100 genes ranked based on correlation of expression with 1q21.1 copy number. The function of two top
genes from 1q21.1, CHD1L/ALC1 and PRKAB2, was studied in detail in LBCs from a deletion and a duplication
carrier. CHD1L/ALC1 is an enzyme with a role in chromatin modification and DNA damage response while PRKAB2
is a member of the AMP kinase complex, which senses and maintains systemic and cellular energy balance. The
protein levels for CHD1L/ALC1 and PRKAB2 were changed in concordance with their copy number in both LBCs. A
defect in chromatin remodeling was documented based on impaired decatenation (chromatid untangling)
checkpoint (DCC) in both LBCs. This defect, reproduced by CHD1L/ALC1 siRNA, identifies a new role of CHD1L/ALC1
in DCC. Both LBCs also showed elevated levels of micronuclei following treatment with a Topoisomerase II
inhibitor suggesting increased DNA breaks. AMP kinase function, specifically in the deletion containing LBCs, was
attenuated.
Conclusion: Our studies are unique as they show for the first time that the 1q21.1 CNV not only causes changes
in the expression of its key integral genes, associated with changes at the protein level, but also results in changes
in their known function, in the case of AMPK, and newly identified function such as DCC activation in the case of
CHD1L/ALC1. Our results support the use of patient lymphoblasts for dissecting the functional sequelae of genes
integral to CNVs in carrier cell lines, ultimately enhancing understanding of biological processes which may
contribute to the clinical phenotype.
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Copy number changes of 1q21.1 chromosomal region
(OMIM 612474 and 612475) have been associated with
variable phenotypes which include ID and/or autism
[1,2], schizophrenia [3-5], congenital heart anomalies
[2,6-8], dysmorphic features [1,6,7] or a normal pheno-
type [1,2]. Deletions and duplications of 1q21.1 were
detected in 0.24% and 0.12% of cases respectively [9], and
in 1/4737 controls [2]. The 1q21.1 critical region spans
approximately 1.35 Mb (from 145 to 146.35 Mb, accord-
ing to NCBI build 36) [2] and includes at least 12 genes.
T h ec a u s eo ft h ep h e n o t y p i cv a r i a b i l i t ya s s o c i a t e dw i t h
1q21.1 copy number variant (CNV) remains largely unex-
plained; however recent studies show that the presence of
“two hit” CNVs can contribute to variability associated
with CNVs that escape syndromic classification [10].
The impact of the 1q21.1 CNV, beyond the clinical
description of affected subjects, is unknown. Tradition-
ally, the functional impact of CNVs is studied in mouse
models where expression changes in 83% of genes from
CNVs were reported in at least one, but frequently in
several, mouse tissues studied [11,12]. Mouse models of
human microdeletion/microduplication disorders such
as DiGeorge [13] and Smith Magenis syndrome [14],
also helped to detect expression changes at the mRNA
and protein levels of genes integral to CNVs and iden-
tify the critical candidate genes for the phenotype (e.g.
transcription factors Tbx1 for DiGeorge and RAI1 for
Smith Magenis syndrome). Subsequent studies of
mutant forms of these genes in transfected human cell
lines showed their abnormal function at the cellular
level (i.e. changed transcriptional activity and/or abnor-
mal sub-cellular localization/stability of the protein
[15,16]). Unfortunately, functional consequences of
genes integral to CNVs in cells/tissues from carriers are
rarely studied, due to unavailability of appropriate
human tissues and the rarity of patients with individual
CNVs [17]. Nevertheless, in rare cases where human
lymphoblasts were used to assess gene expression in
CNV carriers, changes within the CNV and genome
wide were noted [18,19] suggesting that peripheral
blood cells can be used for assessment of the effect of
gene copy number change. Subsequent studies of the
function of genes showing expression changes in cells
from CNV carriers have not yet been reported.
Our study aimed to understand the impact of the
1q21.1 CNV on gene expression genome wide as well as
on the function of a selection of its integral genes in lym-
phoblasts cell lines from clinically well described subjects.
Methods
Subjects
Eight subjects were included in the study and their clini-
cal description provided in Additional File 1, Table S1.
They belong to three families (family A, B and C with 3,
3 and 2 subjects, respectively). Individuals A1, A2, A3,
C1, and C2 were enrolled in a research based array
CGH screening for pathogenic CNVs. The detailed cri-
teria for enrollment were described in Qiao et al. (2010)
[20]. The array CGH study was approved by the Univer-
sity of British Columbia Clinical Research Ethics Board.
Subjects B1 and B2 were ascertained via a clinical genet-
ics service. They had normal karyotypes and Fragile X
testing. B1’s brother, B3, was also ascertained through
clinical genetic service because of the family history of
1q21.2 CNV.
Whole Genome Arrays
The 1q21.1 CNV was detected in all subjects using
initial lower resolution whole genome array analysis as
previously described [20]. Seven of eight subjects were
also analysed subsequently using the new Affymetrix
Cytogenetics Whole-Genome 2.7 M Array (DNA was
not available from B2 for high resolution array analysis).
This higher resolution array contains approximately
400,000 SNP markers and 2.3 million non-polymorphic
markers, with high density coverage across cytogeneti-
cally significant regions. Data was collected using either
GeneChip
® S c a n n e r3 0 0 07Go rG e n e C h i p
® Scanner
3000 Dx and CEL files were analyzed using Affymetrix
Chromosome Analysis Suite software (ChAS v.1.1). The
annotation file used in our analysis can be found on the
Affymetrix website, listed as ArrayNA30.2 (hg18). Addi-
tional CNVs detected with the high resolution array
were compared with the Database of Genomic Variants
http://projects.tcag.ca/variation for overlap with copy
number variants in controls using previously described
criteria for defining common variants [20].
Fluorescent in-situ hybridization (FISH)
Rearrangements at 1q21.1 were confirmed by FISH fol-
lowing previously described protocols [21]. FISH probes
used are listed in Additional File 1, Table S1.
Whole genome expression
RNA from EBV (Epstein Barr Virus) transformed lym-
phoblastoid cell lines was used to study gene expression
in subjects with a 1q21.1 microdeletion (A1-3), micro-
duplication (C1 & C2), and in 3 normal controls. Tran-
script levels were assayed using a commercial whole
genome expression array (Illumina, HumanRef-8 v3.0
Expression BeadChip) using standard protocols. Array
hybridization, washing, blocking, and streptavadin-Cy3
staining were also done according to standard protocols
(Illumina). The BeadChip was then scanned using an
Illumina BeadArray Reader to quantitatively detect
fluorescence emission by Cy3. Eight arrays were run in
parallel on a single BeadChip. Each array contained ~
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base Build 36.2, Release 22), present multiple times on a
single array.
Expression Data Analysis
Background-corrected intensity values were generated
for each probe using GenomeStudio software (Illumina).
Subsequent analyses were carried out in R http://www.
R-project.org/. The data were quantile normalized and
differential expression with respect to 1q21.1 copy num-
ber analyzed using limma [22], with Benjamini-Hoch-
berg multiple test correction to control the false
discovery rate (FDR). This yields a ranking of the genes
used in subsequent analyses.
The ranking of genes from the 2.5 Mb and 5 Mb
flanking regions of 1q21.1 (57 and 150 genes respec-
tively) were examined in the full ranking provided by
the analysis described above, and tested for enrichment
using the Wilcoxon rank-sum test as well as the hyper-
geometric distribution considering just the 100 genes
with the highest expression/1q21.1 copy number
correlation.
In silico functional analysis of top 100 genes
Genes which ranked highest (top 100 genes) in the
expression/1q21.1 copy number correlation analysis
were selected for further in silico functional analysis. An
over-representation analysis (ORA) for Gene Ontology
(GO) terms was performed using ermineJ http://www.
chibi.ubc.ca/ermineJ/[23]. GO terms considered included
biological processes, molecular functions, and cellular
components. The ORA analysis was run using the fol-
lowing settings: gene set sizes were restricted from to 3-
200 genes and best scoring replicates were used for any
replicate genes in the datasets.
Functional studies
Cell culture
EBV-transformed patient-derived LBCs were cultured in
RPMI with 15% FCS (fetal calf serum), L-Gln and anti-
biotics (Pen-Strep) at 5% CO2.T h eW e r n e rs y n d r o m e
LBCs (WRN) were from a WRN syndrome patient
homozygous for the p.Arg368X pathogenic mutation.
A549 adenocarcinoma cells were maintained in MEM
with 10% FCS.
Antibodies and Western blotting analysis
Anti-CHD1L (CHDL1 21703a), MCM2, phospho-S10-
histone H3 and b-tubulin were from Santa Cruz. Anti-
bodies against AMPKb1, AMPKb2 (4148), AMPKa and
AMPKa-pT172, ACC, ACC-pS79 and RAPTOR-pS792
were obtained from Cell Signalling. Whole cell extracts
were prepared by lysing cells in urea buffer (9 M urea,
50 mM Tris-HCl at pH 7.5 and 10 mM 2-mercaptoetha-
nol), followed by 15 s sonication at 30% amplitude using
a micro-tip (SIGMA-Aldrich). The supernatant was
quantified by Bradford Assay. For CHD1L and AMPK-
b2 expression, differing amounts of whole cell extracts
were separated by SDS-PAGE and Western blotting sig-
nals were obtained following ECL (Pierce)-development.
Densiometric quantification of scanned films was
achieved using the Image J Software.
ATM- and ATR-dependent G2-M
G2-M cell cycle checkpoint analysis was carried out as
previously described [17]. Briefly, following irradiation
(3 Gy IR for ATM-dependent or 7 J/m
2 UV for ATR-
dependent) cells were incubated for 4 h in the presence
of 200 ng/mL of Demecolcine prior to swelling, fixation
(Carnoy’s) and staining as described below.
Decatenation Checkpoint Assay (DCC)
Exponentially growing LBCs were treated with 1 μM
ICRF193 (Meso-4,4’-(3,2-butanediyl)-bis(2,6-piperazine-
dione) and 200 ng/mL of Demecolcine and incubated
for 4 h. Cells were harvested, washed 1× in PBS and
swollen in 75 mM KCl for 10 min before fixing with
PBS containing 3% paraformaldehide, 2% Sucrose for 10
min. Following a PBS wash cells were cytospun on to
polylysine coated slides and treated with 0.2% triton X-
100 for 1 min before staining with an anti-phospho-his-
tone H3 polyclonal antibody and secondary detection
using Cy3-conjugated anti-rabbit. Nuclei were counter-
stained with 0.2 μg/mL 4,6-diamidino-2-phenylindole
dilactate (DAPI) and viewed using Nikon E-400 micro-
scope. Approximately 300 cells were counted per
treatment.
CHD1L/ALC1 siRNA and ICRF193 treatment
CHD1L/ALC1 knock out in A549 epithelial lung cancer
cells was done using 20 nM Darmacon SmartPool
siRNA oligos with Metafectine as the transfection
reagent according to the manufacturer’s instructions. 20
h after addition of siRNA, cells were treated with 0.05
μM ICRF193 and 200 ng/mL of Demecolcine and incu-
bated for 4 h. For chromosome spreads cells were swol-
len in 75 mM KCL (10 mins) and fixed in Carnoy’s
(methanol:glacial acetic acid 3:1) for 10 mins, washed
(PBS), dropped onto slides and air dried prior to stain-
ing with Giemsa and imaged using a ZeissAxioplan
microscope. Indirect immunofluoresence using anti-
phospho-Ser10-Histone 10 was also carried out. At least
100 mitotic spreads were counted per treatment.
Pseudomitoses and Micronuclei determination
Cells with entangled chromosomes were considered to
represent pseudomitoses. Their frequency was deter-
mined relative to interphase cells (mean no. of inter-
phase cells counted per treatment = 300).
The levels of micronuclei (MN) were enumerated in
cytochalasin B-induced binucleate [24] cells following
exposure to and recovery from a low dose of ICRF193.
The MN present in binucleate cells are derived from the
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treated for 16 hrs with 0.1 μM ICRF193. The drug was
removed, cells washed in PBS and treated with cytocha-
lasin B (1.5 μg/ml) for a further 24 hrs. Cells were pel-
leted, fixed in Carnoy’s, stained with DAPI and,
cytospun onto poly-L-Lysine coated slides and viewed
using a Nikon E-400 microscope. At least 100 binucleate
cells were enumerated per treatment.
Results
Clinical and genomic findings
The clinical and genomic findings for all eight 1q21.1
CNV carriers are presented in Additional File 1, Table
S1 and Figure 1. The clinical assessment included prena-
tal history and prenatal/newborn complications were
documented in 5/8 cases. In addition, detailed clinical
evaluation of 1q21.1 CNV carriers, both affected as well
as those initially considered to be normal, was per-
formed. This resulted in recognition of learning pro-
blems of various degrees in all studied subjects,
although 2/6 subjects (A3 and C2) had very subtle
learning difficulties as A3 did not complete secondary
school training and C2 admitted having to work very
hard to pass grades. Learning difficulties of variable
degree were therefore common to all subjects, while
other features varied, within and between families.
In family A, the phenotypes of three 1q21.1 deletion
carriers showed different severity despite identical
1q21.1 gene content and almost identical 1q21.1 break-
points (Additional File 1, Table S1 and Figure 1) as
determined by high resolution 2.7 M Affymetrix array.
In family B, phenotypes also differed between indivi-
duals, with individual B3 showing the least severe phe-
notype despite having the largest genomic imbalance
which included both a deletion and a duplication. In
family C, the affected proband (C1) inherited the dupli-
cation from his father, who was apparently normal but
reported mild ADHD as child (not treated) and difficul-
ties in passing grades in school.
The core genes seen in all subjects with a 1q21.1 CNV
are PRKAB2, PDIA3P, FMO5, CHD1L/ALC1, BCL9,
ACP6, GJA5, GJA8, GPR89B, GPR89C, PDZK1P1,a n d
Chr1 (q21.1)
Figure 1 Comparison of genomic overlap for 1q21.1 CNVs. CNV breakpoints were determined using Affymetrix 2.7 M whole genome array
for all subjects except B2 whose breakpoints were determined using a SignatureChip WG v1.1. Red bars indicate deletion of 1q21.1 region while
blue bars indicate a duplication. The previously reported minimal deletion region is shown in green. Genes seen in the majority of our cases
(core genes) are highlighted in yellow.
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considered pathogenic and contributing to the
phenotype.
Whole genome expression analysis
Gene expression analysis was performed for 3 subjects
with microdeletion (A1-3, from family A) two subjects
with microduplication (C1 and C2 from family C) and 3
controls. Ranking of genes was based on correlation of
expression changes and 1q21.1 copy number. Significant
enrichment of gene transcripts from the 1q21.1 CNV
(6/11 with probes on Illumina array) was detected
within the top 100 genes in our 1q21.1 copy number/
expression correlation analysis (Additional File 1, Table
S2 and Figure 2). Transcripts from these genes
(PRKAB2, CHD1L/ALC1, BCL9, ACP6, GPR89A,a n d
PDIA3P) are ranked higher in our analysis than would
be expected by chance (p = 2.5 × 10
-14)a n da r ep o s i -
tively correlated with 1q21.1 copy number with the
exception of PDIA3P.
CHD1L/ALC1, a gene within the 1q21.1 CNV, was at
the top of the correlation list, i.e. the correlation of its
expression and copy number change was the least likely
to have occurred by chance (p = 2.42 × 10
-5, though not
significant after multiple test correction). The p values
for the correlation of expression and 1q21.1 copy num-
ber for all probes across all chromosomes is shown in
Additional File 2, Figure S1. We did not find any
Figure 2 Correlation of expression and copy number for probes from chromosome 1 expressed as log10 of the p values (see
Methods). The probes from 1q21.1 region are in black.
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genes flanking the CNV (2.5 or 5 Mb windows; Wil-
coxon rank-sum test and hypergeometric tests p > 0.2,
see Methods). Gene Ontology enrichment analysis did
not reveal any GO terms with more genes from the top
100 than would be expected by chance.
Gene function analysis
Gene function analysis was performed using LBCs from
B1 and C1. B1 represented the 1q21.1 deletion (Del)
and C1 represented the 1q21.1 duplication (Dup). Two
genes, CHD1L/ALC1 and PRKAB2,f r o m1 q 2 1 . 1w e r e
studied because they ranked highest in the expression/
1q21.1 copy number correlation analysis (CHD1L/ALC1
position 1 and PRKAB2 position 10) and because they
have functions in relevant cellular processes (see below
and discussion for details). The protein expression of
these genes was determined using Western blotting in
patient LBCs. Reduction of protein level for both
CHD1L/ALC1 and PRKAB2 w a ss e e ni nt h eL B C sw i t h
1q21.1 Del and an increase in the LBCs with 1q21.1
Dup in comparison to the control (Figure 3A and 3B
and 5A respectively).
Functional assays for CHD1L/ALC1
CHD1L/ALC1 (hereafter referred to as CHD1L)h a sb e e n
implicated in chromatin remodeling and DNA relaxation
process required for DNA replication, repair and tran-
scription [25]. Both depletion and over-expression of
CHD1L have been implicated in impaired chromatin
remodeling during DNA single strand break repair [26]
suggesting that it is a dosage-sensitive gene with a role in
DNA Damage Response (DDR). The DDR incorporates
DNA repair processes as well as signal transduction pro-
cesses and is coordinated by two protein kinases ATM
(Ataxia Telangiectasia Mutated) and ATR (Ataxia Telan-
giectasia Mutated Rad3-related) that sense DNA damage
and co-ordinate appropriate cell cycle checkpoint activa-
tion, DNA repair and apoptosis [27].
We set out to probe DDR function in 1q21.1 CNV
LBCs by initially examining the ATM and ATR-depen-
dent G2-M checkpoint via mitotic index enumeration
following ionising radiation (IR; for ATM-dependent
arrest) or UV irradiation (for ATR-dependent arrest)
respectively. LBCs with a deletion or duplication of
1q21.1 exhibited normal arrest, as evidenced by an
increase in G2 cells and decrease in mitotic cell index,
suggesting functional ATM and ATR-dependent check-
point activation (data not shown). But, in the course of
this analysis we noticed elevated levels of ‘pseudomitosis’
in LBCs containing 1q21.1 Del and Dup containing cell
lines, which prompted more detailed analysis of their
frequencies in the 1q21.1 Del and Dup cell lines. Pseu-
domitotic cells exhibit catenated entangled chromatids
and their presence indicates sub-optimal Decatenation
Checkpoint (DCC) activation (Figure 3C). The DCC is a
functional cell cycle checkpoint, involving proteins such
as ATR, ATM, WRN, MDC1, BRCA1 and RAD9, that
delays cells in G2 phase until DNA is fully decatenated
[28]. Chromosome catenation is a normal by-product of
DNA replication as replication forks attempt to merge
producing intertwined catenated sister chromatids (Fig-
ure 3C). Topoisomerase II alpha (Topo IIa) specifically
functions to decatenate/untangle these chromosomes by
transient introduction of a DNA double strand break
(DSB) allowing one strand to pass through the other
thereby facilitating completi o no fD N Ar e p l i c a t i o na n d
faithful chromosome segregation (Figure 3C). DCC can
be activated following treatment with a bisdioxopipera-
zine Topo II catalytic inhibitor that prevents Topo-II-
dependent DSB formation (e.g. ICRF193).
Interestingly, we found that LBCs carrying a Del or
D u po f1 q 2 1 . 1f a i l e dt oa r r e s ti nG 2f o l l o w i n gT o p oI I
inhibition, and instead, exhibited elevated pseudomitosis
similar to WRN-defective cells from a patient with Wer-
ner syndrome (OMIM #277700, Figure 3D), which are
known to exhibit defective DCC activation [29]. Consid-
ering that CHD1L functions as a chromatin remodeler
[26], and that catenated chromosomes are a conceivable
outcome of an inability to efficiently manipulate chro-
matin structure, we sought to determine whether reduc-
tion of CHD1L specifically could underlie this
phenotype. Using careful titration of CHD1L siRNA in
A549 cells so as to mimic the patient LBC situation
(Figure 4A), we found that modestly reduced CHD1L
was indeed associated with impaired DCC activation fol-
lowing Topo II inhibition and resulted in increase in
number of pseudomitoses (Figure 4B). These data
describe a novel consequence of limiting CHD1L levels.
Failure of the DCC can also ultimately result in chro-
mosome breakage and elevated levels of genomic
instability as evidenced by increase in micronuclei
[30,31]. Consistent with DDC failure observed in 1q21.1
Del and Dup containing LBCs, we found elevated levels
of micronuclei in both LBCs following prolonged treat-
ment (16 hrs) with ICRF193, although to a greater
extent in the 1q21.1 Del containing LBCs compared to
the 1q21.1 Dup containing LBCs (Figure 4C). Neverthe-
less, these data are consistent with a failure to efficiently
activate the DCC and with elevated levels of DSBs
which manifest as micronuclei in these cultures (Figure
4C). There was no evidence of spontaneous chromo-
some instability or increased micronuclei formation in
the 1q21.1 Del and 1q21.1 Dup containing cell lines
based on analysis of solid stained and G banded patient
chromosomes and nuclei after short term culture.
Functional assays for PRKAB2
AMP-activated protein kinase (AMPK) senses and regu-
lates systemic and cellular energy balance by regulating
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tasis [32]. It also plays an important role in negatively
regulating the mTOR pathway that functions to control
ribosome and protein biosynthesis [33]. AMPK is a het-
erotrimeric complex composed of a catalytic a-subunit,
a regulatory b-subunit and an ADP/ATP-binding g-sub-
unit [34]. Furthermore, several isoforms of each subunit
exist (a1, a2, b1, b2, g1, g2, g3) thereby enabling the
generation of multiple distinct heterotrimeric complexes.
PRKAB2 encodes the b2-isoform of AMPK.
Expression of PRKAB2 protein product, AMPKb2, in
patient cells was decreased in the cell line with 1q21.1
Del and increased in the cell line with 1q21.1 Dup com-
pared to a wild-type (WT) control, whilst that of the b1
subunit was unaffected (Figure 5A and 5B). The gene
encoding AMPK-b1 subunit (PRKAB1) is located on
chromosome 12q24.1 and so is not within the 1q21.1
CNV. To investigate the impact of increased and
decreased AMPK-b2 expression on AMPK activity we
treated patient-derived LBCs with AICAR (N
1-(b-D-
Ribofuranosyl)-5-aminoimidazole-4-carboxamide), a cell
permeable nucleoside analogue that mimics the effects
of AMP on the allosteric activation of AMPK, and mon-
itored phosphorylation of AMPK on threonine-172 (p-
Figure 3 Functional assays for CHD1L in patient cells. (A) Left panels: Western analysis of CHD1L expression from wild-type (WT), 1q21.1
deletion (Del) and duplication (Dup) LBCs following titration of whole cell extracts. Right Panels: b-tubulin re-probe to confirm equal loading.
(B). Densiometric quantification of CHD1L expression from Western analysis from low (black bar), intermediate (white) to higher (grey) amounts
of protein, from each line, using three separate determinations, normalized to b-tubulin loading (a.u. arbitrary units). p = 0.009 for Del and p <
0.005 for Dup compared to WT. (C). The Decatenation Checkpoint (DCC). Unreplicated DNA sequences between converging replication forks
undergo catenation and torsional tension which is normally relieved by Topoisomerase IIa (Topo IIa) which induces a transient DSB enabling
decatenation (untangling). DCC activation in G2 prevents entry into mitosis until sister chromatids are fully separated. DCC can be activated by
Topo II inhibitors arresting the cycle in G2 (indicated in red). DCC failure is monitored by the enumeration of ‘pseudomitosis’ containing highly
catenated (entangled) chromatids. Inset image shows typical pseudomitotic cells following treatment of the Del LBCs with the Topo II inhibitor,
ICRF-193. (D). Mitotic index (Mitosis %) and Pseudomitotic index (Pseudomitosis %) for untreated (Unt) LBCs or ICRF-193 treated, for wild-type
(WT), Werner’s syndrome (WRN), Dup and Del containing LBCs. WRN LBCs are known to be defective in DCC activation. Data presented indicates
the mean ± s.d of three separate determinations. p < 0.005 for reduction in Mitosis (%) Unt compared to ICRF-193 and p < 0.005 for increase in
Pseudomitosis (%) Unt compared to ICRF-193.
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required for and diagnostic of AMPK activity (Figure
5C). Interestingly, both the 1q21.1 Dup and 1q21.1 Del
containing LBCs exhibited slightly elevated basal levels
of p-T172-AMPKa in the absence of AICAR (0 time),
compared to wild-type (WT). Elevated AICAR-induced
p-T172-AMPKa was detectable in wild-type LBCs (WT)
within 5 minutes, and to a similar extent 1q21.1 Dup
containing cells (Figure 5C). In comparison, the change
in the AICAR-induced p-T172-AMPKa activity at 5
minutes was less apparent in the 1q21.1 Del containing
cell line, and the activity remained constant at 15 min-
utes. In contrast, the AICAR-induced p-T172-AMPKa
activity of the WT and 1q21.1 Dup containing cell line
was reduced after 15 minutes. This suggests that
decreased AMPK-b2 level is associated with somewhat
unresponsive AMPK activation, while the 1q21.1 dupli-
cation-containing LBC (Dup) showed similar pattern of
responsiveness to WT cells under these conditions (Fig-
ure 5C).
To further substantiate these findings we explored
AMPK-mediated phosphorylation of two of its well
known substrates, Acetyl-CoA Carboxylase (ACC)
and RAPTOR. ACC is a key mediator of fatty acid
(FA) synthesis. AMPK-induced phosphorylation of
ACC on serine-79 (p-S79-ACC) inhibits ACC enzy-
matic activity thereby limiting FA synthesis under
energy limiting conditions (i.e. high [AMP] and low
[ATP]) [32]. Consistent with our findings with p-
T172-AMPKa, we found efficient induction of p-S79-
ACC in WT and LBCs with 1q21.1 Dup within 5
minutes of AICAR treatment, whilst the LBCs with
1q21.1 Del failed to exhibit significant levels of p-
S79-ACC under these conditions. This data supports
the observation of sub-optimal AMPK activity in this
line (Figure 5D).
Figure 4 Consequences of limiting CHD1L levels by siRNA. (A). Careful titration of CHD1L siRNA conditions were undertaken in A549 so as
to mimic haploinsufficient expression of CHD1L. Left panels:These show the Western analysis of whole cell extracts from Untreated (Unt; mock-
treated) control whereas siRNA indicates cells treated with CHD1L siRNA. b-tubulin expression was monitored to confirm equal loading. Right
graph: Densiometric quantification of CHD1L expression, normalized to b-tubulin loading from three separate siRNA experiments. The degree of
CHD1L reduction is very similar to that observed from the 1q21.1 deletion (Del) containing LBC (Fig 3A and B). Data represents the mean ± s.d.
of three separate experiments (a.u. arbitrary units). (B). Inset image shows a typical catenated pseudomitotic cell following CHD1L siRNA-
mediated knockdown in A549 treated with Topo II inhibitor (ICRF-193). The % pseudomitosis were enumerated under various conditions in A549
following CHD1L siRNA-mediated knockdown to mimic haploinsufficiency. Unt (untreated; not treated with ICRF-193), ICRF-193 (treated with
ICRF-193), Con (control siRNA scrambled oligo), CHD1L siRNA (treated with siRNA to mimic CHD1L haploinsufficiency). Data represents the mean
± s.d. of three separate experiments and p < 0.005 for increase in Pseudomitosis (%) following CHD1L siRNA. (C). Inset image shows micronuclei
(MN). The % of ICRF-193-induced MN in binucleate cells were determined in wild type (WT), Dup and Del containing LBLs following a 24 hr
recovery from an overnight treatment with ICRF-193. Data represents the mean ± s.d. of three separate experiments and p = 0.02 for increase %
MN in binucleates for Dup and p < 0.005 for Del containing LBCs.
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Page 8 of 12RAPTOR is an important regulatory component of the
mTOR containing complex 1 (mTORC1) and is
required for optimal mTOR kinase activity [35]. AMPK-
mediated phosphorylation of RAPTOR on serine-792
(p-S792-RAP) inhibits mTORC1 thereby limiting protein
synthesis and inducing cell cycle arrest when cellular
energy is limiting. Again, consistent with sub-optimal
AMPK activity in the 1q21.1 Del containing LBCs, we
found reduced AICAR-induced p-S792-RAPTOR in
these cells in contrast to the 1q21.1 Dup containing line
and the WT control (Figure 5D). Together, these results
suggest that haploinsufficiency of PRKAB2 results in
reduced expression of AMPK-b2 which is associated
with impaired AICAR-induced AMPK activation. In
contrast, duplication of PRKAB2 did not negatively
impact on AMPK activity under the conditions exam-
ined here.
Discussion
We have performed whole genome expression and cell
function studies in carriers of 1q21.1 deletion and
1q21.1 duplication. Our data show that the top genes
ranked based on correlation of expression and 1q21.1
copy number change are significantly enriched for
1q21.1 genes, indicating association of expression and
copy number for ~50% of 1q21.1 CNV genes. Further-
more, we show that the function of proteins coded by
two of the genes from the 1q21.1 CNV, which ranked
Figure 5 Functional assays for PRKAB2 in patient cells. (A). Left panels:Titrated whole cell extracts wereblotted for AMPKb2( e n c o d e db y
PRKAB2) in wild-type (WT),Del and Dup containing LBCs. Right panels:Blots were re-probed with anti-b-tubulin. Graph: Densiometric
quantification of AMPK-b2 expression from titrated extracts, going from low (black bar), intermediate (white) to higher (grey) amounts of protein,
normalized to b-tubulin loading, from three separate determinations (a.u. arbitrary units). p = 0.01 for Del and p < 0.005 for Dup LBCs compared
to WT. (B). AMPK subunit AMPK-b1, encoded by the PRKAB1 gene on chromosome 12q24.1, shows equivalent expression in the wild-type (WT),
Del and Dup containing LBCs. b-tubulin was used to confirm equal loading. (C). AICAR-induced (2 mM) activation of the AMPK kinase was
monitored using phosphorylation of the AMPKa subunit on threonine 172 (p-T172-AMPKa). Dup and Del containing LBCs exhibited higher
levels of p-T172-AMPKa at the 0 time (untreated), relative to wild-type (WT). Only the 1q21.1 Del containing LBCs appeared to be unresponsive
to AICAR-treatment here. Blots were re-probed with for native AMPKa to confirm loading. (D). AICAR-induced (2 mM) activation of AMPK was
evaluated by monitoring phosphorylation of the AMPK substrate Acetyl-CoA Carboxylase on serine 79 (p-S79-ACC). Similar to p-T172-AMPKa, the
Del containing LBCs appear unresponsive to the AICAR treatment. Blots re-probed for native ACC to confirm loading. (E). AICAR-induced
activation of AMPK was also evaluated by phosphorylation of the AMPK substrate RAPTOR on serine 792 (p-S792-RAP) under identical conditions
as in (B) and (C). Again, Del containing LBCs appeared somewhat unresponsive to AICAR. Blots re-probed for MCM2 to confirm loading.
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Page 9 of 12highest in 1q21.1 copy number expression correlation, is
altered in both the deletion and duplication patient cell
lines.
CHD1L, the gene which ranked first in the expression/
1q21.1 copy number correlation, has been implicated in
chromatin remodeling and relaxation as well as DNA
damage response [25,26]. Our studies identified a novel
role for CHD1L in decatenation, which was suspected
based on its known chromatin remodeling function, and
the defective Topo II decatenation checkpoint demon-
strated here in both the 1q21.1 Del and Dup containing
patient cell lines.
It is of interest that the DCC defect detected in the
1q21.1 Del and Dup containing cell lines is comparable
to that seen in cells from Werner syndrome (OMIM
277700), an autosomal recessive disorder, associated
with predisposition to cancer and premature aging,
neither of which were noted in our patients. The only
overlapping feature, short stature, was noted in 5/6 sub-
jects with the 1q21.1 deletion and also reported in sub-
j e c t sf r o mo t h e rc o h o r t s[ 2 ] .P r e v i o u sD C Cs t u d i e so f
Werner syndrome and control cells suggested that DCC
defect per se is not sufficient to cause significant geno-
mic instability, but requires absence or dysfunction of
“caretaker” genes such as ATR, BRCA1 or WRN [29]. It
is possible that in cell lines with 1q21.1 Del and Dup
the DCC defect is not accompanied with other deleter-
ious events and thus the threshold for significant spon-
taneous genomic instability leading to premature cell
senescence/cancer predisposition is not met. We have
not found evidence of spontaneous chromosome
instability in the short term chromosome cultures of
our patients nor has this been previously reported for
any of the1q21.1 CNV subjects who had routine chro-
mosome analysis. Future studies of the association of
CHD1L with other genes in decatenation checkpoint
mechanism may shed more light on the precise role of
CHD1L in DCC. So, whilst the phenotypic consequences
of defective DCC activation in subjects with a 1q21
CNV are unclear, their cellular phenotype does appear
to be consistent with CHD1L dysfunction.
Our findings that the same cellular phenotype is pre-
sent in both the 1q2.1 Del and Dup containing cell
lines, is in keeping with reports [26] that both dosage
imbalances of CHD1L result in identical cellular effects.
Haploinsufficiency and duplication sensitivity is thought
to affect genes regulating balanced expression of other
genes ("master genes” [36]), which is in keeping with
CHD1L’s role as a chromatin remodeler and indirect
regulator of many key biological processes such as repli-
cation, transcription and translation [37]. In that respect,
it is interesting to note that > 18 genes with a role in
chromatin remodeling have been implicated in intellec-
tual disability [38].
PRKAB2, which ranked 10
th in the expression/1q21.1
copy number correlation, encodes the b2-subunit of
AMPK, a key regulator of cellular response to a large
number of external stimuli which modulates energy
levels at the cellular and organism level [39]. The dereg-
ulation of AMPKb2f u n c t i o ni n1 q 2 1 . 1d e l e t i o na n d
duplication carriers was suspected based on a) changes
in levels of AMPKb2 protein (in keeping with the
1q21.1 copy number state and expression level of the
PRKAB2 gene), b) different basal levels of p-T172-
AMPKa in both 1q21.1 Del and Dup containing lines in
comparison to WT, and c) sub-optimal AICAR-induced
phosphorylation of the AMPK substrates ACC and
RAPTOR, which was more obvious in the 1q21.1 Del
containing line. The last observation could be explained
by the fact that AMPK, as a multi protein complex, may
be sensitive to imbalances of its components [36], and
that reduced availability of a regulatory b-isoform, as
occurs here, could impact on AMPK activity more than
over-abundance.
The multifaceted nature of AMPK role in brain func-
tion is of particular interest to the 1q21.1 phenotype
which most consistently includes some form of learning
difficulty. Previous studies showed that alternations of
AMPK activity resulted in profound abnormalities of the
central nervous system in AMPK-b1
-/- knockout mice
which had reduction of AMPK activity [34], whereas the
consequences of AMPK activation remain controversial
as some groups have shown that AMPK activation is
neuroprotective while others show that AMPK overacti-
vation is detrimental [39]. The essential role of AMPK
in brain function is further supported by its inhibition
of the mTOR pathway [32] which is required for learn-
ing and memory [40].
Our studies are the first to report that the function of
two genes integral to 1q21.1 CNV is changed in patient
lymphoblasts and that both genes are likely to be dosage
sensitive. Both genes are expressed in multiple tissues,
including brain [34,41] which may explain the multi-sys-
temic nature of the physical abnormalities, and the fre-
quent involvement of learning difficulty albeit at a very
variable levels. It remains uncertain as to the tissue-spe-
cific consequences of gene function changes in indivi-
duals with 1q21.1 CNV although AMPK is clearly
involved in brain development and homeostasis. We
believe that our investigations are unique as they
pointed to genes for which further functional investiga-
tion in additional carriers and cell lines may prove to be
worthwhile.
The phenotypic variability for some CNVs has been
traditionally explained by genetic and environmental
factors [42]. In that respect it is of interest to note that
CHD1L and PRKAB2 h a v ear o l ei ns e n s i n ga n d
responding to genomic (chromosomal structure) and
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Page 10 of 12metabolic (energy level) stress and therefore their dys-
function may result in a more severe phenotype in indi-
viduals which experienced more adverse environmental
conditions during development. Sequence changes of
other genes from the 1q21.1 region as well as other
genes across the genome that impair their function can-
not be ruled out as a source of variability at this time
and the new whole genome sequencing technologies will
no doubt become useful in future investigations of their
contribution to the development of an abnormal
phenotype.
Conclusion
O u rs t u d i e sa r eu n i q u ea st h e yp r o v i d ee v i d e n c eo f
changes in the function of genes from 1q21.1 CNV in
lymphoblasts from both deletion and duplication car-
riers. Furthermore, they also provide evidence that dele-
tions and duplications can have similar (e.g. DCC
deficiency in 1q21.1 Del and Dup containing LBCs) as
well as differing functional consequences (e.g. less
responsive AICAR-induced AMPK activity in 1q21.1 Del
containing LBCs) depending on the genes and pathways
involved. Our results support the use of patient lympho-
blasts for dissecting the functional sequelae of genes
integral to CNVs in carrier cell lines, ultimately enhan-
cing understanding of biological processes which may
contribute to the clinical phenotype.
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